$SCYX

Scynexis Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Other
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$2.13 ▲0.952%

Last Close

VOLUME

87,825

DAY RANGE

2.055 - 2.21

52 WEEK

1.81 - 10.25

Join Discuss about SCYX with like-minded investors

profile
@viking #StockTraders.NET
recently

Upside: -CNST +67% (to be acquired by Morphosys for $34.00/shr in cash; deal valued at $1.7B) -MITO +42% (receives Orphan Drug Designation from the European Medicines Agency for elamipretide for the treatment of Barth syndrome) -SLCT +21% (First Bancorp to acquire Select Bancorp, Inc. for $18.10/shr in $314M all-stock transaction) -AMC +20% (successfully sold 8.5M shares of its Class A common stock to Mudrick Capital Management, LP; launches AMC Investor Connect) -MDLA +11% (earnings, guidance) -KIN +9.8% (announces positive results from pivotal efficacy study of parvovirus monoclonal antibody for the prevention of deaths in dogs infected by parvovirus) -WORX +9.6% (Interim COO Tim Hannibal to become permanent CEO) -RLX +7.4% (earnings, guidance) -SKLZ +6.7% (acquires technology-driven marketing platform Aarki for $150M cash-stock deal) -SCYX +4.3% (announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections) -FUSN +3.8% (enters into agreement with McMaster University to build radiopharmaceutical manufacturing facility) -SFT +3.3% (executives announce purchase of shares) -AMBA +3.1% (earnings, guidance) -EVOK +2.2% (issued new US patent covering methods of use for Gimoti (metoclopramide) nasal spray) -APPS +1.9% (earnings, guidance) -CANF +1.9% (to Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson) -ETSY +1.3% (acquires global fashion resale marketplace Depop for $1.63B consisting primarily of cash) -AAP +1.2% (earnings, guidance) -KODK +1.2% (issues statement responding to New York Attorney General regarding insider trading evidence) -ZM +1.2% (earnings, guidance) Downside: -IRTC -15% (CEO Michael Coyle steps down due to personal matters; affirms select Q2 guidance) -ENG -14% (registers ~7.14M shares at $2.80/shr) -LIZI -6.8% (earnings) -PROG -4.2% (launches strategic transformation into biotech company) -ADCT -4.1% (files to sell up to 5.6M shares for holders) -OMIC -3.1% (underwriters fully exercise 1.5M share overallotment option) -HPE -1.2% (earnings, guidance

56 Replies 8 👍 7 🔥

profile
@viking #StockTraders.NET
recently

im gonna try $SCYX long here... risking 7.90

55 Replies 11 👍 13 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: $BB, $CLII, $SCYX, $ADMP, $NNDM, $QTT -if i can get borrows later in the day

142 Replies 14 👍 14 🔥

profile
@Math #StockTraders.NET
recently

$SCYX was a great short on Nate's pump pre

64 Replies 14 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$SCYX would have been a great short but missed it

96 Replies 12 👍 13 🔥

profile
@dros #droscrew
recently

+Initiations 1/6: $ARDX $AYX $DNMR $KDNY $LAZR $NBTX $NLTX $OPEN $PTGX $SCYX $SEIC $SRRK $VINC $VLDR $VSTO $WELL . -Initiations 1/6: $SCCO

107 Replies 15 👍 7 🔥

Key Metrics

Market Cap

69.07 M

Beta

1.58

Avg. Volume

289.70 K

Shares Outstanding

32.58 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-15

Next Dividend Date

Company Information

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.

Website:

HQ: 1 Evertrust Plz Fl 13 Jersey City, 07302-3051 New Jersey

Related News